Literature DB >> 19901084

Development of a high-throughput cell-based reporter assay to identify stabilizers of tumor suppressor Pdcd4.

Johanna S Blees1, Tobias Schmid, Cheryl L Thomas, Alyson R Baker, Lauren Benson, Jason R Evans, Ekaterina I Goncharova, Nancy H Colburn, James B McMahon, Curtis J Henrich.   

Abstract

The novel tumor suppressor Pdcd4 affects tumorigenesis by inhibiting translation. Pdcd4 is phosphorylated and subsequently lost by proteasomal degradation in response to tumor-promoting conditions. Here, the authors describe the development of a reporter cell system to monitor the stability of Pdcd4. The phosphorylation-dependent degradation domain ("target") or an adjacent ("off-target") region of Pdcd4 was cloned into a luciferase expression system. The target constructs were responsive to Pdcd4 degrading conditions (e.g., TPA, p70(S6K1) overactivation), whereas the off-target constructs remained stable. The system was optimized for and shown to be reliable in a high-throughput compatible 384-well format. Screening of 15,275 pure compounds resulted in a hit rate of 0.30% (>50% inhibition of TPA-induced loss of signal, confirmed by reassay). Among the hits were inhibitors of previously identified critical signaling events for TPA-induced Pdcd4 degradation. One compound was identified to be nonspecific using the off-target control cell line. Screening of 135,678 natural product extracts yielded 42 confirmed, specific hits. Z' averaged 0.58 across 446 plates. Further characterization of active natural products and synthetic compounds is expected to identify novel Pdcd4 stabilizers that may be useful in targeting translation to prevent or treat cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19901084      PMCID: PMC2853809          DOI: 10.1177/1087057109351028

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  32 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

2.  The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation.

Authors:  Hsin-Sheng Yang; Aaron P Jansen; Anton A Komar; Xiaojing Zheng; William C Merrick; Sylvain Costes; Stephen J Lockett; Nahum Sonenberg; Nancy H Colburn
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

3.  Structural basis for inhibition of translation by the tumor suppressor Pdcd4.

Authors:  Nicole LaRonde-LeBlanc; Arti N Santhanam; Alyson R Baker; Alexander Wlodawer; Nancy H Colburn
Journal:  Mol Cell Biol       Date:  2006-10-23       Impact factor: 4.272

4.  Akt phosphorylates and regulates Pdcd4 tumor suppressor protein.

Authors:  Alexey Palamarchuk; Alexey Efanov; Vadim Maximov; Rami I Aqeilan; Carlo M Croce; Yuri Pekarsky
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

5.  Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis.

Authors:  Aaron P Jansen; Corinne E Camalier; Nancy H Colburn
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

6.  Translation inhibitor Pdcd4 is targeted for degradation during tumor promotion.

Authors:  Tobias Schmid; Aaron P Jansen; Alyson R Baker; Glenn Hegamyer; John P Hagan; Nancy H Colburn
Journal:  Cancer Res       Date:  2008-02-22       Impact factor: 12.701

Review 7.  Rapamycins: mechanism of action and cellular resistance.

Authors:  Shile Huang; Mary-Ann Bjornsti; Peter J Houghton
Journal:  Cancer Biol Ther       Date:  2003 May-Jun       Impact factor: 4.742

8.  MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G.

Authors:  Yang Chen; Wei Liu; Tengfei Chao; Yu Zhang; Xingqi Yan; Yanhua Gong; Boqin Qiang; Jiangang Yuan; Maosheng Sun; Xiaozhong Peng
Journal:  Cancer Lett       Date:  2008-11-13       Impact factor: 8.679

9.  Development of LanthaScreen cellular assays for key components within the PI3K/AKT/mTOR pathway.

Authors:  Coby B Carlson; Matthew B Robers; Kurt W Vogel; Thomas Machleidt
Journal:  J Biomol Screen       Date:  2009-02-04

10.  Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity.

Authors:  Aaron P Jansen; Corinne E Camalier; Cristi Stark; Nancy H Colburn
Journal:  Mol Cancer Ther       Date:  2004-02       Impact factor: 6.261

View more
  13 in total

Review 1.  Have tumor suppressor PDCD4 and its counteragent oncogenic miR-21 gone rogue?

Authors:  Matthew R Young; Arti N Santhanam; Noriko Yoshikawa; Nancy H Colburn
Journal:  Mol Interv       Date:  2010-04

2.  Actinopolysporins A-C and tubercidin as a Pdcd4 stabilizer from the halophilic actinomycete Actinopolyspora erythraea YIM 90600.

Authors:  Li-Xing Zhao; Sheng-Xiong Huang; Shu-Kun Tang; Cheng-Lin Jiang; Yanwen Duan; John A Beutler; Curtis J Henrich; James B McMahon; Tobias Schmid; Johanna S Blees; Nancy H Colburn; Scott R Rajski; Ben Shen
Journal:  J Nat Prod       Date:  2011-08-26       Impact factor: 4.050

3.  Cryptocaryols A-H, α-pyrone-containing 1,3-polyols from Cryptocarya sp. implicated in stabilizing the tumor suppressor Pdcd4.

Authors:  Tanja Grkovic; Johanna S Blees; Nancy H Colburn; Tobias Schmid; Cheryl L Thomas; Curtis J Henrich; James B McMahon; Kirk R Gustafson
Journal:  J Nat Prod       Date:  2011-05-03       Impact factor: 4.050

4.  Inflammation-induced loss of Pdcd4 is mediated by phosphorylation-dependent degradation.

Authors:  Tobias Schmid; Magdalena M Bajer; Johanna S Blees; Lisa K Eifler; Larissa Milke; Daniela Rübsamen; Kathrin Schulz; Andreas Weigert; Alyson R Baker; Nancy H Colburn; Bernhard Brüne
Journal:  Carcinogenesis       Date:  2011-07-18       Impact factor: 4.944

5.  Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis.

Authors:  Morgan O'Hayre; Catherina L Salanga; Thomas J Kipps; Davorka Messmer; Pieter C Dorrestein; Tracy M Handel
Journal:  PLoS One       Date:  2010-07-22       Impact factor: 3.240

6.  Characterization of pomiferin triacetate as a novel mTOR and translation inhibitor.

Authors:  Magdalena M Bajer; Michael M Kunze; Johanna S Blees; Heidi R Bokesch; Hanyong Chen; Thilo F Brauss; Zigang Dong; Kirk R Gustafson; Ricardo M Biondi; Curtis J Henrich; James B McMahon; Nancy H Colburn; Tobias Schmid; Bernhard Brüne
Journal:  Biochem Pharmacol       Date:  2014-02-07       Impact factor: 5.858

7.  Phosphoproteomic analysis identifies the tumor suppressor PDCD4 as a RSK substrate negatively regulated by 14-3-3.

Authors:  Jacob A Galan; Kathryn M Geraghty; Geneviève Lavoie; Evgeny Kanshin; Joseph Tcherkezian; Viviane Calabrese; Grace R Jeschke; Benjamin E Turk; Bryan A Ballif; John Blenis; Pierre Thibault; Philippe P Roux
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-07       Impact factor: 11.205

Review 8.  Matching the power of high throughput screening to the chemical diversity of natural products.

Authors:  Curtis J Henrich; John A Beutler
Journal:  Nat Prod Rep       Date:  2013-08-08       Impact factor: 13.423

9.  Total Synthesis of Cryptocaryol A by Enantioselective Iridium-Catalyzed Alcohol C-H Allylation.

Authors:  Felix Perez; Andrew R Waldeck; Michael J Krische
Journal:  Angew Chem Int Ed Engl       Date:  2016-03-11       Impact factor: 15.336

10.  Erioflorin stabilizes the tumor suppressor Pdcd4 by inhibiting its interaction with the E3-ligase β-TrCP1.

Authors:  Johanna S Blees; Heidi R Bokesch; Daniela Rübsamen; Kathrin Schulz; Larissa Milke; Magdalena M Bajer; Kirk R Gustafson; Curtis J Henrich; James B McMahon; Nancy H Colburn; Tobias Schmid; Bernhard Brüne
Journal:  PLoS One       Date:  2012-10-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.